Research progress of antibody-drug conjugate targeting B cell maturation antigen in treatment of relapsed/refractory multiple myeloma

Abstract

Multiple myeloma (MM) is one of the most common types of malignant plasmacytosis. At present, most MM patients still cannot be cured. With rapid development of immunotherapy based on hematological malignancies, the use of antibody-drug conjugate (ADC) GSK2857916 has become a new research hot spot in the treatment of relapsed/refractory multiple myeloma (RRMM). GSK2857916 specifically binds to target cell surface through monoclonal antibodies of B cell maturation antigen (BCMA). Then GSK2857916 is rapidly internalized by the target cell, and plays the role of killing MM cells by releasing the active drug mcMMAF. GSK2857916 is one of the promising immunotherapies for the treatment of RRMM. It has high safety and significant clinical efficacy in the treatment of RRMM patients. This article reviews advances in the study of ADC targeting BCMA in the treatment of RRMM, in order to evaluate the safety and tolerance of GSK2857916 monotherapy for RRMM, and further improve the efficacy and prognosis of patients with RRMM. Key words: Multiple myeloma; B-cell maturation antigen; Recurrence; Clinical trial; GSK2857916